EP Patent

EP1108425A1 — New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles

Assigned to Laboratorio Medinfar-Produtos Farmaceuticos SA · Expires 2001-06-20 · 25y expired

What this patent protects

The present invention relates to new oral multi-unitary pharmaceutical preparations containing substituted benzimidazoles being inhibitors of H + , K + -ATPase (i.e. omeprazole, lansoprazole, pantoprazole, leminoprazole and pariprazole) or their pharmaceutically acceptabl…

USPTO Abstract

The present invention relates to new oral multi-unitary pharmaceutical preparations containing substituted benzimidazoles being inhibitors of H + , K + -ATPase (i.e. omeprazole, lansoprazole, pantoprazole, leminoprazole and pariprazole) or their pharmaceutically acceptable salts. Such pharmaceutical preparations are stable pellet preparations containing substituted benzimidazole(s) or their salts and they comprise a quantity of active ingredient of between I and 50 mg, an inert core of spherical symmetry with a diameter of 600 - 1000 µm, constituted by inert excipients, coated with an active layer containing at least one substituted benzimidazole in the micronized form and various pharmaceutically acceptable inert excipients, mixed in suitable proportions in order to allow the disaggregation of the formulations and dissolution of the active ingredient(s) in an appropriate manner, coated in turn with an insulating layer of a strictly polymeric nature, soluble in water, free from alkaline and/or alkaline-earthy metallic salts, of a minimum thickness of 15 µm, this layer being coated lastly with a gastroresistant or enteric layer of a minimum thickness of 30 µm. This invention also refers to the process for the preparation of said pharmaceutical preparations.

Drugs covered by this patent

Patent Metadata

Patent number
EP1108425A1
Jurisdiction
EP
Classification
Expires
2001-06-20
Drug substance claim
No
Drug product claim
No
Assignee
Laboratorio Medinfar-Produtos Farmaceuticos SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.